Search results
Results from the WOW.Com Content Network
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most ...
Cancer and nausea are associated in about fifty percent of people affected by cancer. [1] This may be as a result of the cancer itself, or as an effect of the treatment such as chemotherapy, radiation therapy, or other medication such as opiates used for pain relief. About 70–80% of people undergoing chemotherapy experience nausea or vomiting.
The systems of the body most affected by chemotherapy drugs include visual and semantic memory, attention and motor coordination and executive functioning. [9] [10] These effects can impair a chemotherapy patient's ability to understand and make decisions regarding treatment, perform in school or employment and can reduce quality of life. [10]
For premium support please call: 800-290-4726 more ways to reach us
Nausea and vomiting can be extremely distressing for patients, and so is one of their major concerns. [10] Vomiting has been associated with major complications, such as pulmonary aspiration of gastric content, and might endanger surgical outcomes after certain procedures, for example after maxillofacial surgery with wired jaws.
Nausea after eating can be a symptom of many conditions, like ulcers, acid reflux, anxiety, and more. Doctors explain what can make you feel sick after eating. 11 Reasons Why You May Feel Sick ...
Two oral cancer drugs -- Sutent from Pfizer (PFE) and Afinitor from Novartis (NVS) -- have been found to be effective against the rare form of pancreatic cancer that Apple (AAPL) CEO Steve Jobs ...
In the EPC trial, in which bicalutamide monotherapy (150 mg/day) was evaluated for treatment of early prostate cancer in 8,113 men, the incidence of abnormal liver function tests at 3-year median follow-up was 3.4% for bicalutamide plus standard care (n=4,052) and 1.9% for standard care alone (n=4,061).